Literature DB >> 749923

Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer.

H P Lohrmann, W Schreml, M Lang, M Betzler, T M Fliedner, H Heimpel.   

Abstract

Adjuvant chemotherapy allows a study of the effects of cytotoxic drugs on natural human haematopoiesis. We describe serial studies of granulopoiesis performed during and after intermittent adjuvant chemotherapy for breast cancer (adriamycin plus cyclophosphamide, given for six courses at monthly intervals). After drug administration, a sequential wave of depletion and regeneration through successive granulopoietic compartments was observed. With repeated chemotherapy, moderate neutropenia developed, and the blood CFU-C pool size became progressively reduced. After the sixth chemotherapeutic course, granulopoietic regeneration was delayed. Following discontinuation of chemotherapy, a long-lasting (greater than 200 d) reduction of the blood CFU-C pool size, together with neutropenia and reduction of marrow segmented neutrophils, was observed, suggesting a defect of granulopoiesis with persistent granulopoietic hypoplasia. In patients with expected long survival, residual bone marrow damage should be added to the list of potential late side effects of cytotoxic drug therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 749923     DOI: 10.1111/j.1365-2141.1978.tb05808.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.

Authors:  A D Elias; R Mazanet; C Wheeler; K Anderson; L Ayash; G Schwartz; I Tepler; S Pap; J Pelaez; M Hunt
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to adriamycin in vitro.

Authors:  G E Umbach; G Spitzer; B Drewinko; G Gercovich; G Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.

Authors:  Toshiki Kazama; Nancy Swanston; Donald A Podoloff; Homer A Macapinlac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

4.  Tolerance of hemopoiesis for repeated cytotoxic drug therapy.

Authors:  H P Lohrmann
Journal:  Blut       Date:  1979-10

5.  Adjuvant chemotherapy of breast cancer: hope--reality--hazard?

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1984-02-15

6.  Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.

Authors:  G E Umbach; G Spitzer; J A Ajani; V Hug; H Thames; F B Rudolph; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

7.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Reaction of human granulopoiesis to high-dose cyclophosphamide therapy.

Authors:  H P Lohrmann; W Schreml; T M Fliedner; H Heimpel
Journal:  Blut       Date:  1979-01-22

9.  No effects of levamisole on cytotoxic drug-induced changes of human granulopoiesis.

Authors:  W Schreml; H P Lohrmann
Journal:  Blut       Date:  1979-04-20

10.  Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays.

Authors:  G E Umbach; V Hug; G Spitzer; B Tomasovic; H Thames; J A Ajani; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.